MarketCap
Facebook
X
Telegram
PhaseBio Pharmaceuticals Revenue | PHAS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue PhaseBio Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 10.8 M | 320 K | 2.36 M | 668 K | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.8 M | 320 K | 3.54 M |
Quarterly Revenue PhaseBio Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 208 K | 117 K | - | 335 K | 10.3 M | - | - | - | - | 320 K | - | 241 K | 703 K | 653 K | - | 411 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.3 M | 117 K | 1.48 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cyclerion Therapeutics
CYCN
|
2.07 M | $ 34.99 | 3.77 % | $ 147 M |  USA |
 |
Alector
ALEC
|
21 M | $ 1.87 | -5.08 % | $ 193 M | USA |
 |
Kronos Bio
KRON
|
9.85 M | - | 1.49 % | $ 50.8 M | USA |
 |
Landos Biopharma
LABP
|
18 M | - | 0.58 % | $ 144 M | USA |
 |
Provention Bio
PRVB
|
12.9 M | - | - | $ 2.37 B | USA |
 |
Poseida Therapeutics
PSTX
|
64.7 M | - | - | $ 857 M | USA |
 |
PolarityTE
PTE
|
814 K | - | -0.82 % | $ 1.78 M | USA |
 |
Reata Pharmaceuticals
RETA
|
2.22 M | - | - | $ 6.29 B | USA |
 |
ALX Oncology Holdings
ALXO
|
1.18 M | $ 1.15 | -7.26 % | $ 61.7 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
21.1 M | - | - | $ 23.9 M | USA |
 |
SpringWorks Therapeutics
SWTX
|
192 M | - | - | $ 3.48 B | USA |
 |
Ascendis Pharma A/S
ASND
|
720 M | $ 238.9 | 1.95 % | $ 14.5 B |  Danmark |
 |
Trevena
TRVN
|
567 K | - | -46.58 % | $ 31.8 M | USA |
 |
Y-mAbs Therapeutics
YMAB
|
87.7 M | - | - | $ 382 M | USA |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
Navidea Biopharmaceuticals
NAVB
|
65.7 K | - | -2.99 % | $ 2.47 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
BELLUS Health
BLU
|
16 K | - | - | $ 2.47 B |  Canada |
 |
bluebird bio
BLUE
|
83.8 M | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
199 M | - | - | $ 13.6 B | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
CASI Pharmaceuticals
CASI
|
43.1 M | - | - | $ 35.4 M | USA |
 |
Inventiva S.A.
IVA
|
9.2 M | $ 3.55 | 8.9 % | $ 212 M |  France |
 |
Turning Point Therapeutics
TPTX
|
30.8 M | - | -0.13 % | $ 3.73 B | USA |
 |
Epizyme
EPZM
|
37.4 M | - | - | $ 249 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 26.2 | 1.0 % | $ 1.22 B | USA |
 |
Forward Pharma A/S
FWP
|
1.25 B | - | -0.75 % | $ 18.7 M | Danmark |
 |
Regulus Therapeutics
RGLS
|
10 M | - | - | $ 155 M | USA |
 |
Marinus Pharmaceuticals
MRNS
|
31 M | - | - | $ 29.6 M | USA |
 |
NeuBase Therapeutics
NBSE
|
-416 K | - | -1.56 % | $ 12.3 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
54 K | - | -6.81 % | $ 3.04 B | USA |
 |
scPharmaceuticals
SCPH
|
36.3 M | - | - | $ 218 M | USA |
 |
Athersys
ATHX
|
5.32 M | - | 3.77 % | $ 22.4 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
3.02 B | $ 20.2 | 1.81 % | $ 6.33 B | USA |
 |
Sigilon Therapeutics
SGTX
|
12.9 M | - | - | $ 728 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
TRACON Pharmaceuticals
TCON
|
12 M | - | -1.38 % | $ 46.8 M | USA |
 |
Revance Therapeutics
RVNC
|
234 M | - | - | $ 309 M | USA |